$CARM
Carisma Therapeutics Inc. Stock $carm

$carm Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000148500316000198 Filed on November 14, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$825.0K	$28.65M	$565.0K
YoY Change	46.02%	42661.19%	50.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.750M	$6.370M	$2.320M
YoY Change	18.53%	137.69%	4.98%
% of Gross Profit
Research & Development	$2.800M	$2.754M	$8.080M
YoY Change	-65.35%	-59.17%	53.61%
% of Gross Profit
Depreciation & Amortization	$70.00K	$20.00K	$80.00K
YoY Change	-12.5%	-80.0%	-20.0%
% of Gross Profit
Operating Expenses	$4.447M	$9.120M	$10.40M
YoY Change	-57.25%	-3.25%	39.26%
Operating Profit	-$3.622M	$19.53M	-$9.838M
YoY Change	-63.18%	-308.68%	38.66%
Interest Expense	$0.00	$0.00	-$420.0K
YoY Change	-100.0%	-100.0%	200.0%
% of Operating Profit		0.0%
Other Income/Expense, Net	-$820.0K	-$43.00K	-$70.00K
YoY Change	1071.43%	-87.13%	-92.31%
Pretax Income	-$3.530M	$19.49M	-$10.33M
YoY Change	-65.83%	-301.14%	26.9%
Income Tax	$10.00K
% Of Pretax Income
Net Earnings	-$3.531M	$19.49M	-$10.33M
YoY Change	-65.81%	-301.04%	26.91%
Net Earnings / Revenue	-428.0%	68.02%	-1828.14%
Basic Earnings Per Share	-$0.15	$0.95
Diluted Earnings Per Share	-$0.15	$0.91	-$528.4K
COMMON SHARES
Basic Shares Outstanding	24.24M shares	20.50M shares	19.59M shares
Diluted Shares Outstanding		21.42M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.30M	$30.70M	$36.10M
YoY Change	-29.92%	-33.84%	-33.27%
Cash & Equivalents	$25.34M	$30.72M	$36.08M
Short-Term Investments
Other Short-Term Assets	$600.0K	$1.100M	$200.0K
YoY Change	200.0%	57.14%	-33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$25.93M	$31.81M	$36.31M
YoY Change	-28.6%	-32.34%	-33.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$796.0K	$894.0K	$407.0K
YoY Change	95.58%	86.25%	-16.26%
Goodwill	$16.86M	$10.31M	$0.00
YoY Change
Intangibles	$60.50M	$36.20M	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$350.0K	$13.00K
YoY Change	-100.0%	2400.0%	-31.58%
Total Long-Term Assets	$78.17M	$47.77M	$514.0K
YoY Change	15108.17%	8023.47%	-14.19%
TOTAL ASSETS
Total Short-Term Assets	$25.93M	$31.81M	$36.31M
Total Long-Term Assets	$78.17M	$47.77M	$514.0K
Total Assets	$104.1M	$79.58M	$36.83M
YoY Change	182.68%	67.17%	-33.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.667M	$1.761M	$1.246M
YoY Change	33.79%	-22.73%	-49.31%
Accrued Expenses	$1.774M	$2.492M	$1.794M
YoY Change	-1.11%	117.45%	-9.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$4.100M
YoY Change	-100.0%	-100.0%	1266.67%
Total Short-Term Liabilities	$3.980M	$6.265M	$7.580M
YoY Change	-47.49%	-17.64%	45.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$9.800M
YoY Change	-100.0%	-100.0%	1.03%
Other Long-Term Liabilities	$0.00	$0.00	$423.0K
YoY Change	-100.0%	-100.0%	10475.0%
Total Long-Term Liabilities	$0.00	$0.00	$423.0K
YoY Change	-100.0%	-100.0%	10475.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.980M	$6.265M	$7.580M
Total Long-Term Liabilities	$0.00	$0.00	$423.0K
Total Liabilities	$3.980M	$6.265M	$8.003M
YoY Change	-50.27%	-20.52%	53.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$123.3M	-$119.8M	-$125.2M
YoY Change	-1.51%	4.27%	36.46%
Common Stock	$25.00K	$24.00K	$20.00K
YoY Change	25.0%	20.0%	11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.68M	$41.45M	$18.94M
YoY Change
Total Liabilities & Shareholders Equity	$104.1M	$79.58M	$36.83M
YoY Change	182.68%	67.17%	-33.05%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	-$3.531M	$19.49M	-$10.33M
YoY Change	-65.81%	-301.04%	26.91%
Depreciation, Depletion And Amortization	$70.00K	$20.00K	$80.00K
YoY Change	-12.5%	-80.0%	-20.0%
Cash From Operating Activities	-$5.520M	$21.70M	-$9.380M
YoY Change	-41.15%	-384.03%	31.37%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$40.00K	$420.0K
YoY Change
Cash From Investing Activities	$40.00K	$420.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.0K	120.0K	-900.0K
YoY Change	-111.11%	-76.47%	-103.56%
NET CHANGE
Cash From Operating Activities	-5.520M	21.70M	-9.380M
Cash From Investing Activities	40.00K	420.0K	0.000
Cash From Financing Activities	100.0K	120.0K	-900.0K
Net Change In Cash	-5.380M	22.24M	-10.28M
YoY Change	-47.67%	-411.92%	-156.76%
FREE CASH FLOW
Cash From Operating Activities	-$5.520M	$21.70M	-$9.380M
Capital Expenditures			$0.00
Free Cash Flow			-$9.380M
YoY Change			31.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001485003
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24238369	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Eleven Biotherapeutics, Inc.
	dei	Trading Symbol TradingSymbol	EBIO
	ebio	Change In Fair Value Of Preferred Stock Warrants ChangeInFairValueOfPreferredStockWarrants	38000	USD
CY2016Q3	ebio	Collaboration Revenue CollaborationRevenue	0	USD
	ebio	Collaboration Revenue CollaborationRevenue	400000	USD
CY2016Q3	ebio	Fair Value Assets Liabilities Transfer Between Levels FairValueAssetsLiabilitiesTransferBetweenLevels	0	USD
	ebio	Fair Value Assets Liabilities Transfer Between Levels FairValueAssetsLiabilitiesTransferBetweenLevels	0	USD
CY2016Q3	ebio	Fair Value Changes In Valuation Techniques FairValueChangesInValuationTechniques	0	USD
	ebio	Fair Value Changes In Valuation Techniques FairValueChangesInValuationTechniques	0	USD
	ebio	Issuance Of Warrant For Common Stock IssuanceOfWarrantForCommonStock	328000	USD
	ebio	Issuance Of Warrant For Common Stock IssuanceOfWarrantForCommonStock	0	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	6488000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3129496	shares
CY2016Q3	us-gaap	Construction Payable Current ConstructionPayableCurrent	1156000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	406000	USD
CY2016Q3	ebio	Working Capital Net WorkingCapitalNet	25500000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1246000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1761000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1794000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2492000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	194000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	355000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	144126000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	161201000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000	USD
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3129496	shares
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2686374	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2782613	shares
CY2015Q4	us-gaap	Assets Assets	36825000	USD
CY2016Q3	us-gaap	Assets Assets	79578000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	36311000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	31812000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	36079000	USD
CY2016Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	30716000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2500000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2016Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	21900000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	136000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54059000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46362000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36079000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30716000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30700000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7697000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5363000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19619124	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24155161	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19619124	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24155161	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	931000	USD
CY2016Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	697000	USD
CY2015Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1250000	USD
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2016Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	9774000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	292000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	111000	USD
CY2015Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	115000	USD
CY2016Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	77000	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	115000	USD
CY2016Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	77000	USD
CY2015Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2016Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	50000	USD
CY2016Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	117000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	573000	USD
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	855000	USD
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2400000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M22D
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3186000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-38000	USD
CY2015	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2015	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y11M1D
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y2M1D
CY2015	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7067
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.8759
CY2015	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0106
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0059
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	48568000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	14000	USD
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-915000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2681000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7531000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6366000	USD
	us-gaap	Interest Paid InterestPaid	663000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11984000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-972000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	10312000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-179000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-648000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-568000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1189000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-35000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	844000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	311000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	0	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	10000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2016Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	36200000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-407000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-247000	USD
	us-gaap	Interest Paid InterestPaid	644000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	88000	USD
CY2016Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36825000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79578000	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	13279000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7580000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6265000	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	115000	USD
CY2016Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	21977000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	9763000	USD
CY2016Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17737000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13920000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-286000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	419000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25148000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8138000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-9693000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23123000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	19487000	USD
	us-gaap	Net Income Loss NetIncomeLoss	5422000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-334000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2235000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1066000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4134000	USD
	us-gaap	Operating Expenses OperatingExpenses	22668000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9359000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25358000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	19530000	USD
CY2016Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	9426000	USD
	us-gaap	Operating Expenses OperatingExpenses	25783000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	9120000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	26000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	286000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-283000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	0	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	126000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	350000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2016Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	65000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	423000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	73000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3207000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	96000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	67000	USD
CY2016Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	1410889000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	232000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	952000	USD
	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	1750000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12675000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	62000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	204000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	407000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	894000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	14124000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6745000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18252000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2754000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10684000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	94000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	94000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18806000	shares
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	10000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	1300000	USD
	us-gaap	Restructuring Charges RestructuringCharges	582000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	1300000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1900000	USD
CY2016Q2	us-gaap	Restructuring Costs RestructuringCosts	600000	USD
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2016Q2	us-gaap	Restructuring Reserve RestructuringReserve	582337000	USD
CY2016Q3	us-gaap	Restructuring Reserve RestructuringReserve	509000000	USD
CY2016Q3	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	1338072000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125202000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119800000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119780000	USD
CY2015Q3	us-gaap	Revenues Revenues	67000	USD
	us-gaap	Revenues Revenues	425000	USD
CY2016Q3	us-gaap	Revenues Revenues	28650000	USD
	us-gaap	Revenues Revenues	29156000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	629000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1895000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2144000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3351000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1606002	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.18
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	494787	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1747495	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1803574	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2714756	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.28
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.60
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2530001	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.69
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.30
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.69
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	13525000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	341526	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	18944000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	41445000	USD
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	928404	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	791736	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19345000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18806000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21423000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20495000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20796000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19345000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20004000	shares
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	221000	USD

Files In Submission

Name	View Source	Status
0001485003-16-000198-index-headers.html	Edgar Link	pending
0001485003-16-000198-index.html	Edgar Link	pending
0001485003-16-000198.txt	Edgar Link	pending
0001485003-16-000198-xbrl.zip	Edgar Link	pending
ebio-093016x10q.htm	Edgar Link	pending
ebio-093016x311.htm	Edgar Link	pending
ebio-093016x312.htm	Edgar Link	pending
ebio-093016x321.htm	Edgar Link	pending
ebio-20160930.xml	Edgar Link	completed
ebio-20160930.xsd	Edgar Link	pending
ebio-20160930_cal.xml	Edgar Link	unprocessable
ebio-20160930_def.xml	Edgar Link	unprocessable
ebio-20160930_lab.xml	Edgar Link	unprocessable
ebio-20160930_pre.xml	Edgar Link	unprocessable
ebiolandlordsignature.jpg	Edgar Link	pending
ebiotenantsignaturea01.jpg	Edgar Link	pending
elevenbioterminationagt.htm	Edgar Link	pending
elevenbioterminationa_image1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CARM
Carisma Therapeutics Inc. Stock $carm

2016 Q4 Form 10-Q Financial Statement

#000148500316000198 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM Carisma Therapeutics Inc. Stock $carm

2016 Q4 Form 10-Q Financial Statement

#000148500316000198 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM
Carisma Therapeutics Inc. Stock $carm